Study of Immune Response to Hepatitis B Vaccination in Acute Lymphoblastic Leukemia(ALL) Patients in the Maintenance Phase of Chemotherapy in Ali Asghar Hospital

HBV is hepatotrophic virus that usually causes infection without any symptoms and it is a very important infective factor in patients with acute lymphoblastic leukemia because they need blood products during their treatment. Because of the importance of this subject the aim of this study was to use hepatitis B virus vaccination in patients who did not have immunity for this disease. Patients and We used double dose hepatitis B virus vaccination for prevention of hepatitis B in 159 patients with acute lymphoblastic leukemia that were in maintenance phase of chemotherapy. Patients immunity system(humoral and cellular) and hepatic function was checked and didnt have any problem. This was a case – control study for which Chi-Square Test was used to analyse data. The results(Hepatitis B Surface antibody) were checked in both groups 3-5 months after vaccination. 25% of patients showed affirmative response to vaccination and it was a hopeful sign for increasing researches and control in these patients. Studies in other countries, show about 30% positive response to HbsAg vaccination and we can conclude that, it is better to use hepatitis B virus vaccination for those who dont have any protective antibody for hepatitis B disease.